6221-06-3

Usage

Uses

Used in Organic Synthesis:
METHYL 5-FORMYLNICOTINATE is used as a synthetic intermediate for the preparation of various organic compounds. Its formyl group can be reduced to a hydroxymethyl group or oxidized to a carboxyl group, while the methyl ester can be hydrolyzed to a carboxylic acid. These transformations enable the synthesis of a wide range of products, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, METHYL 5-FORMYLNICOTINATE is used as a key building block for the synthesis of various drug molecules. Its reactivity and functional groups make it suitable for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
METHYL 5-FORMYLNICOTINATE also finds application in the agrochemical industry, where it is used as a precursor for the synthesis of active ingredients in pesticides and other crop protection products. Its versatility in organic synthesis allows for the creation of novel compounds with improved efficacy and selectivity.
Used in Specialty Chemicals:
In the specialty chemicals sector, METHYL 5-FORMYLNICOTINATE is employed as a starting material for the production of various high-value compounds. Its unique properties and reactivity make it an attractive candidate for the development of new materials with specific applications, such as in the fields of polymers, dyes, and fragrances.

Upstream product

• 29681-44-5 5-bromo-3-pyridine carboxylic acid methyl ester 
• 201230-82-2 carbon monoxide 
• 119072-55-8 tert-butylisonitrile 
• 27828-71-3 5-hydroxynicotinic acid 
• 37669-64-0 (5-bromopyridin-3-yl)methanol 
• 123924-98-1 (Z)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-isopropyl-3-benzyloxybenzylamine hydrochloride 
• 129747-52-0 methyl 5-(hydroxymethyl)pyridine-3-carboxylate 
• 1268245-99-3 C₁₃H₁₇NO₄ 
• 223563-60-8 C₁₁H₁₄BrNO₂ 

Downstream Products

• 893723-55-2 5-formylpyridine-3-carboxylic acid 

Relevant academic research and scientific papers

HETEROCYCLIC FXR MODULATORS

The present technology is directed to compounds of formula (I), compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease.

PROBES FOR IMAGING HUNTINGTIN PROTEIN

Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.

NOVEL FXR (NR1H4 ) BINDING AND ACTIVITY MODULATING COMPOUNDS

The present invention relates to compounds which bind to the NR1 H4 receptor (FXR) and act as agonists of the NR1 H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.

Gonadotropin releasing hormone receptor antagonists

The present invention relates to Gonadotropin Releasing Hormone (“GnRH”) (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists.

COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA

Compounds of Formula (I): wherein n, m, p, q, Y, R1 R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.

Substituted alkylamine derivatives

The substituted alkylamine derivatives represented by formula (I) STR1 wherein R1 represents (a) substituted or unsubstituted C2-6 alkenyl group, (b) substituted or unsubstituted C3-6 cycloalkenyl group, (c) substituted or unsubstituted C2-6 alkynyl group, (d) substituted or unsubstituted aryl group, (e) substituted or unsubstituted heterocyclic group, (f) fused heterocyclic group which may be substituted, or (g) group represented by the formula Ru11 -Ar wherein R11 is a heterocyclic group and Ar is a 5- or 6-membered aromatic ring which may contain a hetero N, O or S atom, and which may be substituted; STR2 represents a 5- or 6-membered aromatic ring which may contain a hetero N, O or S atom, and may be substituted by R7, X and Y are linking groups, R2 is H or lower alkyl, R3 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl or lower cycloalkyl, R4 and R5 are independently hydrogen or halogen atoms, R6 represents (a) substituted or unsubstituted acyclic hydrocarbon group which may be unsaturated, (b) substituted or unsubstituted cycloalkyl group, or (c) substituted or unsubstituted phenyl group, or non-toxic salts thereof. (E)-N-(6-6-dimethyl-2-hepten-4-ynyl)-N-ethyl-3-[4-(3-thienyl)-2-thienyl-methyloxy]benzylamine hydrochloride is a representative example. The substituted alkylamine derivatives are useful as pharmaceuticals, particularly for the treatment and prevention of hypercholesterolemia, hyperlipemia and arteriosclerosis.